Objective： To observe the clinical effect of Manlyman Spray combined with biofeedback therapy in the treatment of premature ejaculation (PE)．Methods： A total of 60 primary premature ejaculation patients with stable sexual partners and regular sexual activity (≥１ times per week) from April 2021 to October 2022 were involved in the clinical observation, The patients' age is (34.3 ± 4.9) years old, and the course of the disease is (112.5 ± 65.5) months, and Manlyman Spray combined with biofeedback therapy was used to treat patients for 8 weeks. Manlyman Spray was sprayed 3 times on the surface of the penisqd for 4 weeks, and Biofeedback therapy is treated twice a week according to the AI setting module, for a total of 8 weeks. Before and 8 weeks after medication and at 4 weeks after drug withdrawal, the Intravaginal Ejaculation Latency Time (IELT), Premature Ejaculation Diagnostic Tool (PEDT) scores and Clinical Global Impression of Change (CGIC) scores were Obtained and compared. Results： After 8 weeks of treatment, the IELT of the patients was significantly prolonged (［351.4 ± 76.7］ vs ［87 ± 16.8］,P<0.05) and at 4 weeks after drug withdrawal, the therapeutic effect still existed (［345.9 ± 80.3］ vs ［87 ± 16.8］,P<0.05), the PEDT scores were significantly improved after treatment (［18.2 ± 1.1］ vs ［9.0 ± 1.4］,P<0.05)and at 4 weeks after drug withdrawal(［18.0 ± 1.2］ vs ［9.0 ± 1.4］,P<0.05), and so were the CGIC scores (［13.4 ± 1.3］ vs ［3.3 ± 1.4］,P<0.05, and ［12.6 ± 1.6］ vs ［3.3 ± 1.4］,P<0.05). Conclusion： The combination of Manlyman Spray and biofeedback therapy can effectively treat primary premature ejaculation, with a long duration of treatment and good safety, and the specific mechanism needs further study.
Keywords: premature ejaculation; manlyman spray; biofeedback therapy; efficacy.